Kirkland Advises EQT-Led Consortium on the £4.5B Recommended Cash Offer for Dechra Pharmaceuticals PLC

Kirkland & Ellis is advising a consortium led by EQT with minority investment from Luxinva (a wholly owned subsidiary of the Abu Dhabi Investment Authority ("ADIA") managed by the Private Equities department of ADIA), on the recommended cash offer for the entire issued, and to be issued, ordinary share capital of Dechra Pharmaceuticals PLC, proposed to be structured as a scheme of arrangement. The acquisition values Dechra's entire issued, and to be issued, ordinary share capital at approximately £4.5bn on a fully diluted basis, and implies an enterprise value of £4.9bn.

Read EQT’s transaction announcement

The Kirkland team was led by corporate partners Roger Johnson, Dipak Bhundia, Francesca Harris and Adrian Duncan and associates Charles Hébert, Sher Lin Wong, Luke Forryan, Oliver Weighill and Dan Sarkin; antitrust partners Sally Evans and Athina Van Melkebeke; technology & IP transactions partner John Patten and associate Elizabeth Wauchope; and tax partner Timothy Lowe and associates Maria Clezy and Rohit Pisal.